120 related articles for article (PubMed ID: 2767108)
41. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
Menczer J; Ben-Baruch G; Moran O; Lipitz S
Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
[TBL] [Abstract][Full Text] [Related]
42. The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses.
Dolgun ZN; Kabaca C; Karateke A; İyibozkurt C; İnan C; Altıntaş AS; Karadağ C
Balkan Med J; 2017 Apr; 34(2):156-162. PubMed ID: 28418343
[TBL] [Abstract][Full Text] [Related]
43. Women with a pelvic mass: indicators of malignancy.
Balbi GC; Musone R; Menditto A; Balbi F; Corcioni C; Calabria G; Maciariello C; Balbi C
Eur J Gynaecol Oncol; 2001; 22(6):459-62. PubMed ID: 11874083
[TBL] [Abstract][Full Text] [Related]
44. Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses.
Amirkhosravi A; Bigsby G; Desai H; Rivera-Amaya M; Coll E; Robles-Carrillo L; Faust P; Waters A; Meyer T; Reyes E; Langer F; Francis JL
Blood Coagul Fibrinolysis; 2013 Jul; 24(5):510-7. PubMed ID: 23406663
[TBL] [Abstract][Full Text] [Related]
45. [Diagnosis of ovarian tumor by measuring tumor markers].
Fukatsu T; Nakashima N; Takeuchi J
Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
[TBL] [Abstract][Full Text] [Related]
46. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
Patsner B; Mann WJ; Chalas E
Obstet Gynecol; 1988 Jun; 71(6 Pt 1):949-50. PubMed ID: 3163416
[No Abstract] [Full Text] [Related]
47. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
48. A study of the monoclonal antibody OC 125 to diagnose malignant ovarian tumors.
Li XG; Chen DX; Schwartz PE; Yang Z
Gynecol Oncol; 1989 Mar; 32(3):327-30. PubMed ID: 2920953
[TBL] [Abstract][Full Text] [Related]
49. Validation of referral guidelines for women with pelvic masses.
Im SS; Gordon AN; Buttin BM; Leath CA; Gostout BS; Shah C; Hatch KD; Wang J; Berman ML
Obstet Gynecol; 2005 Jan; 105(1):35-41. PubMed ID: 15625139
[TBL] [Abstract][Full Text] [Related]
50. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors.
Inoue M; Fujita M; Nakazawa A; Ogawa H; Tanizawa O
Obstet Gynecol; 1992 Mar; 79(3):434-40. PubMed ID: 1346716
[TBL] [Abstract][Full Text] [Related]
51. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
[TBL] [Abstract][Full Text] [Related]
52. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer.
Fayed ST; Ahmad SM; Kassim SK; Khalifa A
Dis Markers; 1998 Nov; 14(3):155-60. PubMed ID: 10427474
[TBL] [Abstract][Full Text] [Related]
53. Risk of malignancy index in preoperative evaluation of pelvic masses.
Ashrafgangooei T; Rezaeezadeh M
Asian Pac J Cancer Prev; 2011; 12(7):1727-30. PubMed ID: 22126553
[TBL] [Abstract][Full Text] [Related]
54. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging.
Weiner Z; Thaler I; Beck D; Rottem S; Deutsch M; Brandes JM
Obstet Gynecol; 1992 Feb; 79(2):159-62. PubMed ID: 1731278
[TBL] [Abstract][Full Text] [Related]
55. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
56. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
Neunteufel W; Breitenecker G
Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
[TBL] [Abstract][Full Text] [Related]
57. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
[TBL] [Abstract][Full Text] [Related]
58. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
Antonić J; Rakar S
Anticancer Res; 1995; 15(4):1527-32. PubMed ID: 7654041
[TBL] [Abstract][Full Text] [Related]
59. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses.
Finkler NJ; Benacerraf B; Lavin PT; Wojciechowski C; Knapp RC
Obstet Gynecol; 1988 Oct; 72(4):659-64. PubMed ID: 3047614
[TBL] [Abstract][Full Text] [Related]
60. Abnormally high values of CA 125 and CA 19-9 in women with benign tumors.
Nagata H; Takahashi K; Yamane Y; Yoshino K; Shibukawa T; Kitao M
Gynecol Obstet Invest; 1989; 28(3):165-8. PubMed ID: 2680806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
